Center for Biomarker Research and Personalized Medicine, Virginia Commonwealth University, Richmond 23298, USA.
JAMA Psychiatry. 2013 Jun;70(6):573-81. doi: 10.1001/jamapsychiatry.2013.288.
Schizophrenia (SCZ) is a devastating psychiatric condition. Identifying the specific genetic variants and pathways that increase susceptibility to SCZ is critical to improve disease understanding and address the urgent need for new drug targets.
To identify SCZ susceptibility genes.
We integrated results from a meta-analysis of 18 genome-wide association studies (GWAS) involving 1,085,772 single-nucleotide polymorphisms (SNPs) and 6 databases that showed significant informativeness for SCZ. The 9380 most promising SNPs were then specifically genotyped in an independent family-based replication study that, after quality control, consisted of 8107 SNPs.
Linkage meta-analysis, brain transcriptome meta-analysis, candidate gene database, OMIM, relevant mouse studies, and expression quantitative trait locus databases.
We included 11,185 cases and 10,768 control subjects from 6 databases and, after quality control 6298 individuals (including 3286 cases) from 1811 nuclear families.
Case-control status for SCZ.
Replication results showed a highly significant enrichment of SNPs with small P values. Of the SNPs with replication values of P.01, the proportion of SNPs that had the same direction of effects as in the GWAS meta-analysis was 89% in the combined ancestry group (sign test, P < 2.20 x 10(-16) and 93% in subjects of European ancestry only (P < 2.20 < 10(-16)). Our results supported the major histocompatibility complex region showing a3.7-fold overall enrichment of replication values of P < .01 in subjects from European ancestry. We replicated SNPs in TCF4 (P = 2.53 x 10(-10)) and NOTCH4 (P = 3.16 x 10(-7)) that are among the most robust SCZ findings. More novel findings included POM121L2 (P = 3.51 x 10(-7)), AS3MT (P = 9.01 x 10(-7)), CNNM2 (P = 6.07 = 10(-7)), and NT5C2(P = 4.09 x 10(-7)). To explore the many small effects, we performed pathway analyses. The most significant pathways involved neuronal function (axonal guidance, neuronal systems, and L1 cell adhesion molecule interaction)and the immune system (antigen processing, cell adhesion molecules relevant to T cells, and translocation to immunological synapse).
We replicated novel SCZ disease genes and pathogenic pathways. Better understanding the molecular and biological mechanisms involved with schizophrenia may improve disease management and may identify new drug targets.
精神分裂症(SCZ)是一种严重的精神疾病。确定增加 SCZ 易感性的特定遗传变异和途径对于改善疾病认识和满足新的药物靶点的迫切需求至关重要。
确定 SCZ 易感基因。
我们整合了 18 项全基因组关联研究(GWAS)的荟萃分析结果,这些研究涉及 1085772 个单核苷酸多态性(SNP)和 6 个显示出对 SCZ 有显著信息量的数据库。然后,在一个独立的基于家庭的复制研究中专门对 9380 个最有希望的 SNP 进行了特定的基因分型,该研究经过质量控制后,包含 8107 个 SNP。
连锁荟萃分析、脑转录组荟萃分析、候选基因数据库、OMIM、相关小鼠研究和表达数量性状基因座数据库。
我们纳入了来自 6 个数据库的 11185 例病例和 10768 例对照,经过质量控制后,来自 1811 个核家庭的 6298 人(包括 3286 例病例)。
SCZ 的病例对照状态。
复制结果显示,具有小 P 值的 SNP 具有高度显著的富集。在具有复制值 P<.01 的 SNP 中,与 GWAS 荟萃分析具有相同作用方向的 SNP 的比例在合并祖系群体中为 89%(符号检验,P<.01 x 10(-16),在仅具有欧洲血统的受试者中为 93%(P<.01 x 10(-16))。我们的结果支持主要组织相容性复合体区域,在具有欧洲血统的受试者中,复制值 P<.01 的总体富集倍数为 3.7 倍。我们复制了 TCF4(P = 2.53 x 10(-10))和 NOTCH4(P = 3.16 x 10(-7))中的 SNP,这是最稳健的 SCZ 发现之一。更具创新性的发现包括 POM121L2(P = 3.51 x 10(-7))、AS3MT(P = 9.01 x 10(-7))、CNNM2(P = 6.07 x 10(-7))和 NT5C2(P = 4.09 x 10(-7))。为了探索许多微小的影响,我们进行了途径分析。最显著的途径涉及神经元功能(轴突导向、神经元系统和 L1 细胞粘附分子相互作用)和免疫系统(抗原加工、与 T 细胞相关的细胞粘附分子和易位到免疫突触)。
我们复制了新的 SCZ 疾病基因和发病途径。更好地了解精神分裂症涉及的分子和生物学机制可以改善疾病管理,并可能确定新的药物靶点。